Bristol Myers Squibb (NYSE:BMY) will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 a share.The deal represents an 88% premium to the closing price ...

It was revealed Monday that Pharma giant Bristol-Myers Squibb will acquire all outstanding shares of 2seventy bio for $5, valuing the deal at ~$286m. 2seventy bio, a Cambridge-based biotech ...

2seventy Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares of 2seventy Bio at a price of $5.00 per share in an ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

Cambridge drugmaker 2seventy bio has agreed to be acquired by Bristol Myers Squibb for approximately $286 million in cash. Bristol Myers Squibb (NYSE: BMY) has been partnering with 2seventy to ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy ...

CAMBRIDGE, Mass., March 11, 2025--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb ...